UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 11, 2005
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Washington
|
|
0-23930
|
|
91-1549568 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1100 Olive Way, Suite 100, Seattle, Washington
|
|
98101 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code (206) 623-7612
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On October 11, 2005, Targeted Genetics Corporation, or the Company, announced initiation
of a Phase I clinical trial of tgAAC94 in patients with inflammatory arthritis. A copy of the
Company’s press release announcing the preliminary results is attached as Exhibit 99.1 to this
current report.
Item 9.01. Financial Statements and Exhibits.
99.1 Press Release Dated October 11, 2005
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
Targeted Genetics Corporation
|
|
| |
By: |
/s/ David J. Poston
|
|
| |
|
David J. Poston |
|
| Dated: October 11, 2005 |
|
Acting Chief Financial Officer
(Principal Financial and Accounting Officer) |
|
3